Giacomo Gianfaldoni

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani et al. · Blood · 2009 · 430 citations · Full text

Medicine, Oncology, Chemotherapy +13

Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab

Antonio M. Risitano, Rosario Notaro, Ludovica Marando et al. · Blood · 2009 · 349 citations · Full text

Medicine, Hematology, Immunology +14

<i>CEBPA</i> –double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features

Francesco Mannelli, Vanessa Ponziani, Sara Bencini et al. · Haematologica · 2016 · 70 citations · Full text

Medicine, Hematology, Oncology +15

Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria

Jörg Schubert, Peter Hillmen, Alexander Röth et al. · British Journal of Haematology · 2008 · 63 citations · Full text

Medicine, Hematology, Pharmacology +16

Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study

Giacomo Gianfaldoni, Francesco Mannelli, Michela Baccini et al. · British Journal of Haematology · 2006 · 49 citations

Medicine, Hematology, Oncology +17